DIG-RHD: Digoxin Effective in Rheumatic Heart Disease

Why It Matters

Digoxin offers a low‑cost, evidence‑based option to curb heart‑failure admissions in rheumatic heart disease, addressing a major unmet need in resource‑limited settings.

Key Takeaways

• Digoxin cut HF events by 4.1% absolute
• Trial enrolled 1,759 RHD patients across India
• No mortality reduction despite fewer hospitalizations
• Toxicity observed in 1.1% of treated patients
• Cost under $600k; highly scalable for low‑income settings

Pulse Analysis

Rheumatic heart disease remains a leading cause of premature death in low‑ and middle‑income countries, yet therapeutic options beyond valve interventions have been scarce. Historically, digoxin’s role in heart‑failure management has been contentious, with observational data suggesting increased mortality, but randomized trials in HFrEF showing neutral effects. The DIG‑RHD study re‑examines this cardiac glycoside in a population where the disease burden is highest, positioning it as an essential medicine that could fill a critical therapeutic gap.

The multicenter Indian trial randomized 880 patients to low‑dose digoxin and 879 to placebo, predominantly young adults with moderate‑to‑severe mitral stenosis. After 2.1 years, the digoxin arm experienced a 4.1‑percentage‑point absolute reduction in the primary composite endpoint, driven by a lower rate of heart‑failure hospitalizations (HR 0.82). Subgroup analysis hinted at greater benefit among those with baseline atrial fibrillation, while overall mortality remained unchanged. Safety signals were minimal, with suspected toxicity in only 1.1% of treated participants, reinforcing the drug’s tolerability when monitored appropriately.

From a policy perspective, the trial’s modest $600,000 budget underscores the feasibility of large‑scale, low‑cost research in emerging markets. Health systems grappling with RHD can now consider integrating digoxin as an adjunct to valve repair or balloon valvuloplasty, potentially easing the hospitalization burden and freeing resources for definitive interventions. Future investigations should explore optimal dosing, long‑term outcomes, and real‑world implementation pathways to cement digoxin’s role in global RHD management.